The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Open accessAbstract
BACKGROUND: Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease-modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated. METHODS: In a multicenter, double-blind, placebo-controlled, delayed-start trial, we randomly assigned patients with early Parkinson's disease to receive levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks (early-start group) or placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks (delayed-start group). The primary outcome was the between-group difference in the mean change from baseline to week 80 in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS; scores range from 0 to 176, with higher scores signifying more severe disease). Secondary analyses included the progression of symptoms, as measured by the UPDRS score, between weeks 4 and 40 and the noninferiority of early initiation of treatment to delayed initiation between weeks 44 and 80, with a noninferiority margin of 0.055 points per week. RESULTS: A total of 445 patients were randomly assigned: 222 to the early-start group and 223 to the delayed-start group. The mean (±SD) UPDRS score at baseline was 28.1±11.4 points in the early-start group and 29.3±12.1 points in the delayed-start group. The change in UPDRS score from baseline to week 80 was -1.0±13.1 points and -2.0±13.0 points, respectively (difference, 1.0 point; 95% confidence interval [CI], -1.5 to 3.5; P=0.44); this finding of no significant between-group difference at week 80 implies that levodopa had no disease-modifying effect. Between weeks 4 and 40, the rate of progression of symptoms, as measured in UPDRS points per week, was 0.04±0.23 in the early-start group and 0.06±0.34 in the delayed-start group (difference, -0.02; 95% CI, -0.07 to 0.03). The corresponding rates between weeks 44 and 80 were 0.10±0.25 and 0.03±0.28 (difference, 0.07; two-sided 90% CI, 0.03 to 0.10); the difference in the rate of progression between weeks 44 and 80 did not meet the criterion for noninferiority of early receipt of levodopa to delayed receipt. The rates of dyskinesia and levodopa-related fluctuations in motor response did not differ significantly between the two groups. CONCLUSIONS: Among patients with early Parkinson's disease who were evaluated over the course of 80 weeks, treatment with levodopa in combination with carbidopa had no disease-modifying effect. (Funded by the Netherlands Organization for Health Research and Development and others; LEAP Current Controlled Trials number, ISRCTN30518857 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Self-citationHughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citationThe Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.295 · Cited by 494
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Recent Developments in Parkinson's Disease
Pearce, J. (1986) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.7.850-c · Cited by 435
PD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.1.67 · Cited by 327
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Schapira, A. H., McDermott, M. P., Barone, P., Comella, C. L., Albrecht, S., Hsu, H. H., Massey, D. H., Mizuno, Y., Poewe, W., Rascol, O., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70117-0 · Cited by 203
van den Berg, B., Brouwer, W., van Exel, J., Koopmanschap, M., van den Bos, G. A. M., & Rutten, F. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.06.046 · Cited by 201
Pinter, M. M., Pogarell, O. M., & Oertel, W. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.436 · Cited by 155
Telemedicine in the Era of Coronavirus Disease 2019 (COVID-19): A Neurosurgical Perspective
Blue, R., Yang, A. I., Zhou, C., De Ravin, E., Teng, C. W., Arguelles, G. R., Huang, V., Wathen, C., Miranda, S. P., Marcotte, P., et al. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.05.066 · Cited by 136
O’Reilly, F., Finnan, F., Allwright, S., Smith, G. D., & Ben‐Shlomo, Y. (1996) · Europe PMC (PubMed Central) · Cited by 130
Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson’s Disease
Ravina, B., Marek, K., Eberly, S., Oakes, D., Kurlan, R., Ascherio, A., Beal, F. M., Beck, J., Flagg, E., Galpern, W., et al. (2012) · Movement Disorders · doi:10.1002/mds.25157 · Cited by 130
Self-citationThe Delayed-Start Study Design
D’Agostino, R. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmsm0904209 · Cited by 119
Mei, S., Eisinger, R. S., Hu, W., Tsuboi, T., Foote, K. D., Hass, C. J., Okun, M. S., Chan, P., & Ramirez‐Zamora, A. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.00001 · Cited by 106
Hernandez, S. M., Tikhonova, E. B., & Karamyshev, A. L. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00072 · Cited by 46
Evaluation of the Dutch version of the Parkinson's Disease Questionnaire 39
Marinus, J., Jeukens‐Visser, M., Jenkinson, C., & Stiggelbout, A. M. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.05.005 · Cited by 38
The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease
Weisscher, N., Post, B., de Haan, R. J., Glas, C. A. W., Speelman, J. D., & Vermeulen, M. (2007) · Neurology · doi:10.1212/01.wnl.0000295666.30948.9d · Cited by 36
Self-citationDepression and major depressive disorder in patients with Parkinson's disease
Inoue, T., Kitagawa, M., Tanaka, T., Nakagawa, S., & Koyama, T. (2009) · Movement Disorders · doi:10.1002/mds.22921 · Cited by 29
Zeissler, M., Li, V., Parmar, M., & Carroll, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191856 · Cited by 27
Verschuur, C. V. M., Suwijn, S. R., Post, B., Dijkgraaf, M. G. W., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Deuschl, G., Lang, A. E., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0491-1 · Cited by 19
Self-citationJiang, S., Berger, S. M., Hu, Y., Bartsch, D., & Tian, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00356 · Cited by 15
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Self-citationParkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Metadata
- Authors
- Verschuur, C. V. M., Suwijn, S. R., Boel, J. A., Post, B., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Munts, A. G., Deuschl, G., Lang, A. E., Dijkgraaf, M. G. W., de Haan, R. J., & de Bie, R. M. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-24
- Volume
- 380
- Issue
- 4
- Pages
- 315-324
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2914468735
- Cited by
- 353
- References
- 28
- FWCI
- 27.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.